Biopharma Cred. Regulatory News (BPCR)

25 March 2025

BIOPHARMA CREDIT PLC 

("BIOPHARMA CREDIT" OR THE "COMPANY") 

DIVIDEND DECLARATION

BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor, is pleased to declare an interim dividend in respect of the quarterly financial period ending 31 March 2025 of 1.75 cents per share, payable on 7 May 2025 to ordinary shareholders on the register as at 4 April 2025. The ex-dividend date will be 3 April 2025. The Company has chosen to designate the entire amount of this interim dividend as an interest distribution. Shareholders in receipt of such a dividend will be treated for UK tax purposes as though they have received a payment of interest. This will result in a reduction in the corporation tax payable by the Company.

The Company targets a base annual dividend of 7 cents per ordinary share and has consistently exceeded that target in recent years. In 2024, 2023 and 2022 the Company has paid a dividend of 10.18 cents, 10.21 cents and 13.08 cents respectively.

The default payment for dividends is in US dollars. However, shareholders can elect to have dividends paid in sterling (GBP) and the option to elect a sterling dividend payment for this dividend will be available to shareholders until 4 April 2025 (the "Election Date").

A copy of the Dividend Currency Election Form, which should be sent to MUFG Corporate Markets Limited, 10th Floor, Central Square, 29 Wellington Street, Leeds LS1 4DL when completed, will be available on the Company's website at www.bpcruk.com/investor-materials. CREST shareholders must elect via CREST.

Past performance is not an indication of future performance.

Enquiries:

BioPharma Credit plc

via MUFG Corporate Governance Limited

Company Secretary

+44 (0) 333 300 1932

Burson Buchanan

Mark Court / Jamie Hooper / Henry Wilson / Samuel Adams

+44 (0) 20 7466 5000

biopharmacredit@buchanan.uk.com

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

LEI: 213800AV55PYXAS7SY24